Blood-based Liquid Biopsy Detects Lymph Node Metastasis in Colorectal Cancer Patients
|
By LabMedica International staff writers Posted on 04 May 2021 |
|
Image: Micrograph of a colorectal adenocarcinoma metastasis to a lymph node. The cancer (forming glands) is seen at the center-top. Adipose tissue is present on the upper right (Photo courtesy of Wikimedia Commons)
A recent paper described a novel, noninvasive liquid biopsy test for detection of lymph node metastasis in individuals with high-risk T1 colorectal cancer.
Local cancer in many parts of the body can cause lymph nodes to enlarge because of tumor cells that have metastasized into the node. Lymph node involvement is often a key factor in the diagnosis and treatment of cancer. As part of the investigations or workup for cancer, lymph nodes may be imaged or even surgically removed. Whether lymph nodes are affected will affect the staging of the cancer and overall treatment and prognosis.
Investigators at City of Hope (Duarte, CA, USA) had previously used surgically resected tissue specimens and endoscopic biopsies taken during colonoscopy to establish a panel of miRNAs and mRNAs for the identification of lymph node metastasis (LNM) in invasive submucosal colorectal cancers (T1 CRC). In the current study, they translated these tissue-based biomarkers into a noninvasive blood-based liquid biopsy assay.
The investigators analyzed 330 specimens from patients with high-risk T1 CRC, which included 188 serum samples from two clinical cohorts and matched FFPE (formalin-fixed-paraffin-embedded) samples. They performed RT-qPCR followed by logistic regression analysis to develop an integrated transcriptomic panel and establish a risk-stratification model, combined with clinical risk factors.
The liquid biopsy test was found to accurately identify lymph node metastasis with high sensitivity (83.3%) and specificity (76.2%). These results enabled the investigators to identify an optimized transcriptomic panel of four miRNAs (miR-181b, miR-193b, miR-195, miR-411) and five mRNAs (AMT, FOXA1, PIGR, MMP1, MMP9), which robustly identified patients with LNM. Application of this diagnostic model limited potential over-treatment to only 18% of all patients, which was dramatically superior to currently used models based on pathological features (92%).
"Since radical surgery dramatically reduces quality of life for patients, improving the success rate of identification of high-risk individuals with lymph node metastasis remains the challenge in T1 colorectal cancer diagnosis," said senior author Dr. Ajay Goel, chair of the department of molecular diagnostics and experimental therapeutics at City of Hope. "In the future, we hope to improve our confidence in identifying which individuals truly have lymph node metastasis via this novel biomarker-based liquid biopsy test for T1 colorectal cancer, in combination with clinical and pathological criteria. Obtaining results with more than 80% accuracy (sensitivity) in finding lymph node metastasis in the blood was a completely unexpected finding and is a complete game changer."
The blood-based liquid biopsy for detection of lymph node metastasis was described in the April 2, 2021, online edition of the journal Gastroenterology.
Related Links:
City of Hope
Local cancer in many parts of the body can cause lymph nodes to enlarge because of tumor cells that have metastasized into the node. Lymph node involvement is often a key factor in the diagnosis and treatment of cancer. As part of the investigations or workup for cancer, lymph nodes may be imaged or even surgically removed. Whether lymph nodes are affected will affect the staging of the cancer and overall treatment and prognosis.
Investigators at City of Hope (Duarte, CA, USA) had previously used surgically resected tissue specimens and endoscopic biopsies taken during colonoscopy to establish a panel of miRNAs and mRNAs for the identification of lymph node metastasis (LNM) in invasive submucosal colorectal cancers (T1 CRC). In the current study, they translated these tissue-based biomarkers into a noninvasive blood-based liquid biopsy assay.
The investigators analyzed 330 specimens from patients with high-risk T1 CRC, which included 188 serum samples from two clinical cohorts and matched FFPE (formalin-fixed-paraffin-embedded) samples. They performed RT-qPCR followed by logistic regression analysis to develop an integrated transcriptomic panel and establish a risk-stratification model, combined with clinical risk factors.
The liquid biopsy test was found to accurately identify lymph node metastasis with high sensitivity (83.3%) and specificity (76.2%). These results enabled the investigators to identify an optimized transcriptomic panel of four miRNAs (miR-181b, miR-193b, miR-195, miR-411) and five mRNAs (AMT, FOXA1, PIGR, MMP1, MMP9), which robustly identified patients with LNM. Application of this diagnostic model limited potential over-treatment to only 18% of all patients, which was dramatically superior to currently used models based on pathological features (92%).
"Since radical surgery dramatically reduces quality of life for patients, improving the success rate of identification of high-risk individuals with lymph node metastasis remains the challenge in T1 colorectal cancer diagnosis," said senior author Dr. Ajay Goel, chair of the department of molecular diagnostics and experimental therapeutics at City of Hope. "In the future, we hope to improve our confidence in identifying which individuals truly have lymph node metastasis via this novel biomarker-based liquid biopsy test for T1 colorectal cancer, in combination with clinical and pathological criteria. Obtaining results with more than 80% accuracy (sensitivity) in finding lymph node metastasis in the blood was a completely unexpected finding and is a complete game changer."
The blood-based liquid biopsy for detection of lymph node metastasis was described in the April 2, 2021, online edition of the journal Gastroenterology.
Related Links:
City of Hope
Gold Member
Aspiration System
VACUSAFE
Prefilled Tubes
Prefilled 5.0ml Tubes
Manual Pipetting Aid
Pipette Controllers macro
Latest Molecular Diagnostics News
- Multiplex PCR Test Differentiates Four Causes of Ulcerative Skin Lesions
- Blood Test Guides Patient Selection for Radiopharmaceutical Therapy in Prostate Cancer
- New Biomarker Helps Guide Combination Therapy for Treatment-Resistant Breast Cancer
- Blood-Based Gene Expression Test Detects Early Pancreatic Cancer
- Blood-Based Biomarker Panel Outperforms Existing Liver Disease Tests
- Fully Automated Test Advances Hepatitis D Diagnosis and Monitoring
- HPV Assay Gains Expanded CE Mark for Self-Collected Vaginal Samples
- Blood Test Achieves Improved Detection of Advanced Precancerous Colorectal Lesions
- Community-Based Genetic Screening Reaches Rural and Vulnerable Populations
- Blood and Urine Liquid Biopsy Detects Early Colorectal Cancer Mutations
- Epigenetic Profiling Could Refine Prognosis in Acute Myeloid Leukemia
- Genetic Risk Score Supports Diagnosis and Prognosis in Idiopathic Pulmonary Fibrosis
- AI Reveals Immune Response Biomarkers Linked to Ebola Survival
- Extracellular Vesicle Marker Identifies Early Lung Adenocarcinoma and Predicts Recurrence
- WHO Adds First Bundibugyo Ebola Molecular Test to Emergency Use Listing
- Blood Test Helps Guide Post-Surgical Treatment in Metastatic Colorectal Cancer
Channels
Clinical Chemistry
view channel
New Machine-Learning Equation Improves LDL Cholesterol Assessment
Accurate assessment of low-density lipoprotein (LDL) cholesterol is central to cardiovascular risk management, yet calculation methods can underestimate values in some patients. Laboratories widely use... Read more
Blood Biomarker May Signal Cognitive Decline Risk a Decade Before Symptoms
Accurately identifying which cognitively healthy older adults will later develop impairment due to Alzheimer’s disease remains difficult, as brain scans and genetic testing provide only part of the risk picture.... Read more
Hematology
view channel
New Marker Helps Detect Aggressive Multiple Myeloma Earlier
Multiple myeloma is an incurable malignancy of plasma cells and the second most common blood cancer worldwide, with more than 188,000 new cases each year. Although therapies have advanced, most patients... Read more
New Biomarkers Predict Resistance to Targeted Therapy in Rare Blood Cancer
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and aggressive leukemia with limited treatment options and a poor prognosis. Although tagraxofusp is the first approved targeted therapy for... Read more
Immunology
view channel
Ultrasensitive Blood Test Detects Sjögren’s Signature Years Before Diagnosis
Sjögren’s disease is a common autoimmune condition that can be difficult to recognize early, leading to delayed diagnosis and persistent symptom burden. It affects around half a million people in the UK... Read more
New Assays Expand Cytokine Testing for Transplant and Immunocompromised Patients
Eurofins Viracor has introduced three plasma-based assays—CXCL9 (Test Code 33607), CXCL10 (Test Code 33609), and interleukin-18 (IL-18) (Test Code 33611)—expanding its immunology testing menu for transplant... Read more
Microbiology
view channel
Syndromic GI Panel Detects Cyclospora for Rapid Case Confirmation
U.S. health authorities have reported a rapid increase in cyclosporiasis since May 2026, with more than 1,600 confirmed infections and thousands of additional suspected cases under investigation.... Read more
Rapid Panel Identifies Gram-Negative Pathogens and Resistance Markers in Bloodstream Infections
Bloodstream infections require rapid identification of causative pathogens and resistance mechanisms to guide effective therapy. Delays in profiling gram-negative organisms, which are frequently associated... Read more
Pathology
view channel
Digital Pathology Tool Predicts Breast Cancer Outcomes and Therapy Response
Breast cancer prognosis often depends on microscopic assessment of tumor architecture, a process that can be subjective and lead to variable predictions across patient groups. Quantitative measures that... Read more
AI Bone Marrow Mapping Provides New Tool to Track Blood Cancer Severity
Myelodysplastic neoplasms, a group of blood cancers that primarily affect older adults, are challenging to stage and monitor, often requiring repeated bone marrow biopsies that can yield uncertain interpretations.... Read more
Technology
view channel
Training Device Improves Accuracy of Pooled Molecular Diagnostics
High-throughput molecular diagnostics have transformed infectious disease detection, but many workflows remain difficult to execute accurately without extensive training. Sample pooling can cut per‑test... Read more
New CE-Certified Software Advances Whole-Genome Cancer Testing
European hospitals are increasingly using comprehensive tumor genomics to guide therapy, but routine whole genome sequencing (WGS) requires validated, regulation-compliant workflows. A newly CE-certified... Read more
National Rare Disease Registry Standardizes Genetic and Clinical Data for Coordinated Care
Rare diseases collectively impose a significant clinical burden despite their individual rarity, often involving multisystem presentations and prolonged diagnostic journeys. Limited specialist expertise... Read more
Industry
view channel
Tempus to Acquire Personalis in $1.5 Billion Precision Oncology Deal
Tempus AI, Inc. (Chicago, IL, USA) has entered into a definitive agreement to acquire Personalis, Inc. (Fremont, CA, USA), expanding its capabilities in molecular residual disease (MRD) testing and cancer... Read more
